Transcriptomic-metabolomic reprogramming in EGFR-mutant NSCLC early adaptive drug escape linking TGFβ2-bioenergetics-mitochondrial priming

The impact of EGFR-mutant NSCLC precision therapy is limited by acquired resistance despite initial excellent response. Classic studies of EGFR-mutant clinical resistance to precision therapy were based on tumor rebiopsies late during clinical tumor progression on therapy. Here, we characterized a n...

Descripción completa

Detalles Bibliográficos
Autores principales: Thiagarajan, Praveena S., Wu, Xiaoliang, Zhang, Wei, Shi, Ivy, Bagai, Rakesh, Leahy, Patrick, Feng, Yan, Veigl, Martina, Lindner, Daniel, Danielpour, David, Yin, Lihong, Rosell, Rafael, Bivona, Trever G., Zhang, Zhenfeng, Ma, Patrick C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Priority Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5347670/
https://www.ncbi.nlm.nih.gov/pubmed/27852038
http://dx.doi.org/10.18632/oncotarget.13307

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5347670/
https://www.ncbi.nlm.nih.gov/pubmed/27852038
http://dx.doi.org/10.18632/oncotarget.13307

Ejemplares similares